- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05939128
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (ERA)
A Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess the BRCA1/2m Prevalence, Treatment Approaches and Outcomes in HER2-negative High-risk Early Breast Cancer Patients in Russia
(Neo)adjuvant treatment approaches and outcomes
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Arkhangelsk, Russia
- Research Site
-
Barnaul, Russia
- Research Site
-
Belgorod, Russia
- Research Site
-
Chelyabinsk, Russia
- Research Site
-
Grozny, Russia
- Research Site
-
Irkutsk, Russia
- Research Site
-
Khanty-Mansiysk, Russia
- Research Site
-
Krasnodar, Russia
- Research Site
-
Krasnoyarsk, Russia
- Research Site
-
Moscow, Russia
- Research Site
-
Nal'chik, Russia
- Research Site
-
Nyzhny Novgorod, Russia
- Research Site
-
Ryazan, Russia
- Research Site
-
Saint Petersburg, Russia
- Research Site
-
Severodvinsk, Russia
- Research Site
-
Sochi, Russia
- Research Site
-
Ufa, Russia
- Research Site
-
Vladivostok, Russia
- Research Site
-
Yaroslavl, Russia
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Study population will consist of early breast cancer HER2-negative patients with high risk of recurrence with available medical history, surgery or biopsy FFPE from primary tumor. It is estimated that approximately 750 patients will be enrolled in approximately 25 sites
Description
Inclusion Criteria:
-
Patients aged ≥ 18 years old
-. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples
-
Early HER2-negative BC (stages 2 and 3)
-
Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation
-
Unknown BRCAm status or negative BRCAm PCR test
-
Performed surgical treatment (not more than 7 months before inclusion)
-. High risk of recurrence according to one or more criteria:
- incomplete pathomorphological response (in case of neoadjuvant therapy)
- CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
- presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
- ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
- Any other high risk criterion according to investigators opinion
-
The presence of postoperative or biopsy FFPE
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 3 months
- Confirmation that the subject was already included in this study before
- Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer
Time Frame: 3 years
|
The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median |
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population
Time Frame: 3 years
|
Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics. |
3 years
|
|
To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Time Frame: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population
Time Frame: 3 years
|
The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis |
3 years
|
|
To determine the prevalence of HRR mutations in HER2-negative breast cancer
Time Frame: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To determine invasive disease-free survival in the HRRm population (including BRCA1/2)
Time Frame: 3 years
|
Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status |
3 years
|
|
To evaluate concordance between P53 expression and BRCAm
Time Frame: 3 years
|
Testing the archived tumour specimen and blood |
3 years
|
|
To assess the quality of life in patients with various types of adjuvant systemic therapy
Time Frame: 3 years
|
completed WHOQOL-BREF questionnaire will be assessed |
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D133HR00030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.